3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Terminated
3
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
19
Sarcoma
4
Gynecologic
4
Gastrointestinal
4
Thoracic
3
Genitourinary
3
Endocrine
3
Breast
3
NET
2
Dermatologic
2
CNS
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Lymphoma
156
Lymphoma, Non-Hodgkin
140
Leukemia, Lymphocytic, Chronic, B-Cell
136
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Lymphoma, Follicular
112
Lymphoma, Large B-Cell, Diffuse
111
Lymphoma, Mantle-Cell
75
Lymphoma, B-Cell
73
Hodgkin Disease
63
Multiple Myeloma
58
Leukemia
55
Burkitt Lymphoma
51
Recurrence
48
Lymphoma, B-Cell, Marginal Zone
48
Leukemia, Myeloid, Acute
47
Neoplasms
45
Myelodysplastic Syndromes
42
Hematologic Neoplasms
34
Waldenstrom Macroglobulinemia
28
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Lymphoma, T-Cell
17
Leukemia, Biphenotypic, Acute
16
Leukemia, B-Cell
16
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
15
Mycosis Fungoides
15
Lymphoproliferative Disorders
15
Lymphoma, T-Cell, Peripheral
15
Myeloproliferative Disorders
14
Lymphoma, T-Cell, Cutaneous
14
Breast Neoplasms
14
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Salivary Gland Neoplasms
×
Lymphoid
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA